ImageneBio (IMA) EBITDA (2020 - 2025)

ImageneBio has disclosed EBITDA across 6 years of filings, most recently posting -$26.6 million for Q3 2025.

• EBITDA for Q3 2025 came in at -$26.6 million, down 1206.19% year-over-year; the trailing twelve-month figure through Sep 2025 was -$69.5 million (down 19.76% YoY), and the FY2024 annual result was -$49.1 million, up 27.18% from the prior year.
• EBITDA came in at -$26.6 million for Q3 2025 at ImageneBio, down from -$8.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $2.8 million in Q4 2021 to a low of -$28.1 million in Q4 2024.
• The 5-year median for EBITDA is -$15.8 million (2024), against an average of -$15.1 million.
• Across the five-year window, EBITDA surged 110.72% in 2021 and slumped 1206.19% in 2025, its largest moves.
• ImageneBio's EBITDA stood at $2.8 million in 2021, then tumbled by 641.33% to -$15.1 million in 2022, then sank by 44.95% to -$21.9 million in 2023, then dropped by 28.33% to -$28.1 million in 2024, then grew by 5.41% to -$26.6 million in 2025.
• The last three EBITDA figures came in at -$26.6 million (Q3 2025), -$8.8 million (Q2 2025), and -$6.0 million (Q1 2025), per Business Quant data.